Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 3/2014

01-05-2014 | Review

Rationale for B cell targeting in SLE

Author: Iñaki Sanz

Published in: Seminars in Immunopathology | Issue 3/2014

Login to get access

Abstract

B cells are central pathogenic players in systemic lupus erythematosus and multiple other autoimmune diseases through antibody production as well as antibody independent function. At the same time, B cells are known to play important regulatory functions that may protect against autoimmune manifestations. Yet, the functional role of different B cell populations and their contribution to disease remain to be understood. The advent of agents that specifically target B cells, in particular anti-CD20 and ant-BLyS antibodies, have demonstrated the efficacy of this approach for the treatment of human autoimmunity. The analysis of patients treated with these and other B cell agents provides a unique opportunity to understand the correlates of clinical response and the significance of different B cell subsets. Here, we discuss this information and how it could be used to better understand SLE and improve the rational design of B cell-directed therapies in this disease.
Literature
1.
2.
Manjarrez-Orduno N, Quach TD, Sanz I (2009) B cells and immunological tolerance. J Invest Dermatol 129(2):278–288PubMedCrossRef
3.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581PubMedCrossRef
4.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232. doi:10.​1056/​NEJMoa0909905 PubMedCentralPubMedCrossRef
5.
6.
Merrill JT, Buyon JP, Furie RA, Latinis KM, Gordon C, Hsieh H-J, Brunetta PG (2011) Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. doi:10.​1177/​0961203310395802​
7.
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, Group LI (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215–1226. doi:10.​1002/​art.​34359 PubMedCrossRef
8.
9.
10.
Sanz I (2014) Pharmacological effects and mechanisms of action of agents blocking B cells. In: Bosch X, Ramos-Casals M, Khamashta MA (eds) Drugs targeting B-cells in autoimmune diseases. Milestones in Drug Therapy. Springer Basel, pp 37–64. doi:10.​1007/​978-3-0348-0706-7_​3
11.
Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol advance online publication
12.
13.
Fillatreau S, Gray D, Anderton SM (2008) Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 8:391–397PubMedCrossRef
14.
Zhong X, Gao W, Degauque N, Bai C, Lu Y, Kenny J, Oukka M, Strom TB, Rothstein TL (2007) Reciprocal generation of Th1/Th17 and Treg by B1 and B2 B cells. Eur J Immunol 9999(9999):NA
15.
Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL, Swain SL, Lund FE (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1(6):475–482PubMedCrossRef
16.
Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, Mauri C (2013) CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 5(173):173ra123. doi:10.​1126/​scitranslmed.​3005407 CrossRef
17.
Chen X, Jensen PE (2007) Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J Immunol 179(4):2046–2050PubMedCrossRef
18.
Olson TS, Bamias G, Naganuma M, Rivera-Nieves J, Burcin TL, Ross W, Morris MA, Pizarro TT, Ernst PB, Cominelli F, Ley K (2004) Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J Clin Invest 114(3):389–398. doi:10.​1172/​jci200420855 PubMedCentralPubMedCrossRef
19.
Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF (2008) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28(5):639–650PubMedCrossRef
20.
Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117(2):530–541. doi:10.​1182/​blood-2010-07-294249 PubMedCentralPubMedCrossRef
21.
Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C (2010) CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32(1):129–140. doi:10.​1016/​j.​immuni.​2009.​11.​009 PubMedCrossRef
22.
23.
Martin F, Chan AC (2006) B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24(1)
24.
25.
Merrell KT, Benschop RJ, Gauld SB, Aviszus K, Decote-Ricardo D, Wysocki LJ, Cambier JC (2006) Identification of anergic B cells within a wild-type repertoire. Immunity 25(6):953–962PubMedCrossRef
26.
Teague BN, Pan Y, Mudd PA, Nakken B, Zhang Q, Szodoray P, Kim-Howard X, Wilson PC, Farris AD (2007) Cutting edge: transitional T3 B cells do not give rise to mature b cells, have undergone selection, and are reduced in murine lupus. J Immunol 178(12):7511–7515PubMedCrossRef
27.
28.
Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, Kuchen S, Lipsky PE (2007) IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 178(5):2872–2882PubMedCrossRef
29.
30.
Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, Plebani A, Kumararatne DS, Bonnet D, Tournilhac O, Tchernia G, Steiniger B, Staudt LM, Casanova J-L, Reynaud C-A, Weill J-C (2004) Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a pre-diversified immunoglobulin repertoire. Blood:2004-2001-0346
31.
32.
33.
34.
35.
36.
Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201(5):703–711PubMedCentralPubMedCrossRef
37.
38.
Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG (2004) Reduced competitiveness of autoantigen-engaged b cells due to increased dependence on BAFF. Immunity 20(4):441–453PubMedCrossRef
39.
40.
41.
Chan TD, Gatto D, Wood K, Camidge T, Basten A, Brink R (2009) Antigen affinity controls rapid T-dependent antibody production by driving the expansion rather than the differentiation or extrafollicular migration of early plasmablasts. J Immunol 183(5):3139–3149. doi:10.​4049/​jimmunol.​0901690 PubMedCrossRef
42.
43.
44.
Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KGC, Dorner T, Hiepe F (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6(10):741–750PubMedCrossRef
45.
46.
Kaji T, Ishige A, Hikida M, Taka J, Hijikata A, Kubo M, Nagashima T, Takahashi Y, Kurosaki T, Okada M, Ohara O, Rajewsky K, Takemori T (2012) Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. J Exp Med 209(11):2079–2097. doi:10.​1084/​jem.​20120127 PubMedCentralPubMedCrossRef
47.
48.
Bernasconi NL, Onai N, Lanzavecchia A (2003) A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood:2002-2011-3569
49.
Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298(5601):2199–2202PubMedCrossRef
50.
Calero I, Nieto JA, Sanz I (2010) B cell therapies for rheumatoid arthritis: beyond B cell depletion. Rheum Dis Clin N Am 36(2):325–343CrossRef
51.
Calero I, Sanz I (2010) Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med 10(54):416–424PubMed
52.
53.
54.
55.
56.
57.
Qian Y, Wei C, Eun-Hyung Lee F, Campbell J, Halliley J, Lee JA, Cai J, Kong YM, Sadat E, Thomson E, Dunn P, Seegmiller AC, Karandikar NJ, Tipton CM, Mosmann T, Sanz I, Scheuermann RH (2010) Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data. Cytometry B Clin Cytom 78B(S1):S69–S82. doi:10.​1002/​cyto.​b.​20554 CrossRef
58.
Palanichamy A, Bernard J, Owen T, Zheng B, Conley T, Quach T, Wei C, Looney J, Sanz I, Anolik JH (2008) Characterization of human late transitional B cells: implications for systemic lupus. Arthritis Rheum 58(9):S446
59.
Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, Sanz I (2007) A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 178(10):6624–6633PubMedCrossRef
60.
61.
Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O’Shea MA, Roby G, Kottilil S, Arthos J, Proschan MA, Chun T-W, Fauci AS (2008) Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 205(8):1797–1805. doi:10.​1084/​jem.​20072683 PubMedCentralPubMedCrossRef
62.
Berkowska MA, Driessen GJA, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, He B, Biermann K, Lange JF, van der Burg M, van Dongen JJM, van Zelm MC (2011) Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 118(8):2150–2158. doi:10.​1182/​blood-2011-04-345579 PubMedCentralPubMedCrossRef
63.
Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3(10):944–950PubMedCrossRef
64.
65.
66.
Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C (2007) Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 178(12):7868–7878PubMedCrossRef
67.
Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178(10):6092–6099PubMedCrossRef
68.
Tan EM (1989) Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93–151PubMedCrossRef
69.
Jenks SA, Palmer EM, Marin EY, Hartson L, Chida AS, Richardson C, Sanz I (2013) 9G4+ autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus. Arthritis Rheum 65(12):3165–3175. doi:10.​1002/​art.​38138 PubMedCrossRef
70.
Cappione A 3rd, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, Sanz I (2005) Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 115(11):3205–3216. doi:10.​1172/​JCI24179 PubMedCentralPubMedCrossRef
71.
Isenberg DA, Garton M, Reichlin MW, Reichlin M (1997) Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. Br J Rheumatol 36(2):229–233PubMedCrossRef
72.
van Vollenhoven RF, Bieber MM, Powell MJ, Gupta PK, Bhat NM, Richards KL, Albano SA, Teng NN (1999) VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics. J Rheumatol 26(8):1727–1733PubMed
73.
Cappione A, Pugh-Bernard A, Sanz A (2002) Lupus VH4.34-encoded antibodies bind to a B220-specific glycoform of CD45 on the surface of human B lymphocytes. Arthritis Rheum 46:S222
74.
Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I (2001) Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 108(7):1061–1070. doi:10.​1172/​JCI12462 PubMedCentralPubMedCrossRef
75.
76.
77.
78.
Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A, Burmester G, Diamond B, Lipsky PE, Dörner T (2008) Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 58(6):1762–1773PubMedCrossRef
79.
80.
Cambier JC (2013) Autoimmunity risk alleles: hotspots in B cell regulatory signaling pathways. J Clin Invest:1–4. doi:10.​1172/​JCI69289
81.
Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50(11):3580–3590PubMedCrossRef
82.
Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50(8):2580–2589PubMedCrossRef
83.
84.
85.
Mei H, Schmidt S, Dorner T (2012) Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther 14(Suppl 5):S1PubMedCentralPubMedCrossRef
86.
87.
88.
89.
Ginzler E, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer N (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14(1):R33PubMedCentralPubMedCrossRef
90.
Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C (2013) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2012-202760
91.
Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand J, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50(8):2580–2589PubMedCrossRef
92.
Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P (2011) B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 63(10):3038–3047. doi:10.​1002/​art.​30466 PubMedCrossRef
93.
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Ikle D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone H, for the R-ITNRG (2013) Clinical outcomes of remission induction therapy for severe ANCA-associated vasculitis. Arthritis Rheum. doi:10.​1002/​art.​38044
94.
Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54(11):3612–3622PubMedCrossRef
95.
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, Group HT (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.[see comment]. N Engl J Med 358(7):676–688PubMedCrossRef
96.
Anolik J, Barnard J, Owen T, Zheng B, Kemshett S, Looney J, Sanz I (2007) Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56(9):3044–3056PubMedCrossRef
97.
Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y (2010) Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol. doi:10.​3899/​jrheum.​100729
98.
Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki V, Iniotaki A, Moutsopoulos HM (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52(2):501–513PubMedCrossRef
99.
van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, Gutierrez-Roelens I, Durez P, Netea MG, van der Meer JWM, van den Berg WB, Joosten LAB (2011) The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 63(6):1507–1516. doi:10.​1002/​art.​30314 PubMedCrossRef
100.
Stasi R, Cooper N, Del Poeta G, Stipa E, Evangelista ML, Abruzzese E, Amadori S (2008) Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood:blood-2007-2012-129262. doi:10.​1182/​blood-2007-12-129262
101.
Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone T-S, Zhong ZJ, Freimuth WW, Chatham WW, on behalf of the B, Groups B-S (2012) Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 64(7):2328–2337. doi:10.​1002/​art.​34400 PubMedCentralPubMedCrossRef
102.
Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A (2010) Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 62(1):201–210PubMedCentralPubMedCrossRef
103.
Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, Houssiau F, Tak PP, Isenberg DA, Kelley L, Kilgallen B, Barry AN, Wegener WA, Goldenberg DM (2013) Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). doi:10.​1093/​rheumatology/​ket129
104.
Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dörner T (2008) Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 67(4):450–457. doi:10.​1136/​ard.​2007.​075762 PubMedCrossRef
105.
Daridon C, Blassfeld D, Reiter K, Mei H, Giesecke C, Goldenberg D, Hansen A, Hostmann A, Frolich D, Dorner T (2010) Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 12(6):R204PubMedCentralPubMedCrossRef
106.
Metadata
Title
Rationale for B cell targeting in SLE
Author
Iñaki Sanz
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 3/2014
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-014-0430-z

Other articles of this Issue 3/2014

Seminars in Immunopathology 3/2014 Go to the issue

Review

B cell-mediated pathogenesis of ANCA-mediated vasculitis

Review

Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases

Editorial

Introduction: B cell-mediated autoimmune diseases

Review

B cells in MS and NMO: pathogenesis and therapy

Review

The pathogenic potential of autoreactive antibodies in rheumatoid arthritis

Review

Plasma cells in immunopathology: concepts and therapeutic strategies

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits